TrialAnnals of hematology2026

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Yunfei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.